195P - Irinotecan plus cetuximab (Cmab) versus irinotecan plus panitumumab (Pmab) in patients (pts) with wild-type (WT) KRAS exon 2 metastatic colorectal...

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Cytotoxic agents
Colon and Rectal Cancer
Rectal Cancer
Presenter Naotoshi Sugimoto
Citation Annals of Oncology (2016) 27 (suppl_9): ix53-ix67. 10.1093/annonc/mdw581
Authors N. Sugimoto, A. Hasegawa, F. Fujisawa, T. Yoshinami, T. Yagi, F. Imamura
  • Clinical Onocology, Osaka Medical Center for Cancer and Cardiovascular Dideases, 537-8511 - Osaka/JP



The phase 3 ASPECCT trial of pts with chemo-refractory WT KRAS exon 2 mCRC demonstrated that Pmab was noninferior to Cmab for overall survival (OS). But few data was existed the comparison of irinotecan plus Cmab (IC) with irinotecan plus Pmab (IP). So we retrospectively compared the efficacy and toxicity of IC to IP in patients with mCRC as third- line in our hospital.


The selection criteria were pathologically proven mCRC; 20 years or older; WT KRAS exon 2; had a previous treatment history of refractory or intolerable of fluoropyrimidine, oxaliplatin and irinotecan; no prior Cmab and Pmab; performance status 0-2; able to oral intake; and adequate organ functions (excluding WJOG6510G enrolled patients).


44 patients were treated IC or IP over the period from December 2008 to January 2016. The analysis covered 34 patients (excluding enrolled WJOG6510G). The median age was 65 years (range 41-88); 24 males and 10 females; PS 0/1/2 score 19/13/2; 23 patients were treated IC and 11 patients were treated IP. Progression-free survival and overall survival were 3.8 and 9.9 months with IC and 6.0 and 10.5 months with IP (no significant difference). The response rate and disease control rate were 17.4% and 56.6% with IC and 63.6% and 88.9% with IP. The rate of grade 3-4 toxicity in IC/IP were leucopenia (8.7%/18.2%), neutorpenia (4.3%/27.3%), anemia (17.4%/18.2%), rash (4.3%/9.1%), pruritus(8.9%/0%), paronytia(13%/9.1%), hypomagnesaemia(8.7%/27.3%) and infusion related reaction (0%/9.1%). There was no treatment death in both groups.


It is suggested that not only IC but also IP can be the option for WT KRAS exon 2 mCRC patients as third-line. The result of WJOG6510G (IC versus IP in pts with WT KRAS exon 2 mCRC as third-line; a multicenter, randomized phase II study) will be reported near future.

Clinical trial indentification

Legal entity responsible for the study

Osaka Medical Center for Cancer and Cardiovascular Diseases




All authors have declared no conflicts of interest.